Literature DB >> 31478996

Safety of Early Repeated Thrombolysis: A Case Report.

Paola Caruso1, Giovanni Furlanis1, Mariana Ridolfi1, Milos Ajcevic1,2, Marcello Naccarato1, Paolo Manganotti1.   

Abstract

INTRODUCTION: Intravenous thrombolysis within 4.5 hours from symptom onset improves functional outcome in acute ischemic stroke patients. Repeated intravenous tissue plasminogen activator (IVtPA) is contraindicated in patients presenting with early recurrent stroke (ERS) within 3 months from the initial stroke because of a greater risk of intracranial hemorrhage. CASE
PRESENTATION: A 59-year-old man presented with ERS, National Institute of Health Stroke Scale of 16, 10 days after a previous stroke. Brain computed tomography (CT) showed a previous hypodensity with 4 cm volume. Angio-CT highlighted the left middle cerebral artery and left internal carotid occlusion. Perfusion CT showed small deep core and large penumbra. The patient underwent IVtPA. After 24 hours, the National Institute of Health Stroke Scale was 7, and CT scan showed an acute ischemic lesion in the left basal ganglia area and frontal lobe without hemorrhagic transformation.
CONCLUSION: This case report suggests that further randomized studies may evaluate whether repeated IVtPA may be safe and effective in ERS occurring shortly after a previous stroke when patients experience a period of complete neurological regression, minor disability, and a small infarct volume. Should the hypothesis be confirmed, small volume core and wide volume penumbra at perfusion CT may support the decision of adopting IVtPA repetition.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31478996     DOI: 10.1097/NRL.0000000000000239

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  1 in total

1.  Wake-up stroke: thrombolysis reduces ischemic lesion volume and neurological deficit.

Authors:  Giovanni Furlanis; Miloš Ajčević; Alex Buoite Stella; Tommaso Cillotto; Paola Caruso; Mariana Ridolfi; Maria Assunta Cova; Marcello Naccarato; Paolo Manganotti
Journal:  J Neurol       Date:  2019-11-12       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.